Short answer
Tesamorelin is a synthetic analogue of growth hormone releasing hormone, stabilised so it resists rapid enzymatic breakdown. It is studied at the GHRH receptor, in pulsatile growth hormone release and in visceral adipose and lipid metabolism models. It is supplied as a lyophilised 5mg or 10mg research vial for laboratory reconstitution.
Tesamorelin is one of the most frequently referenced growth hormone releasing hormone analogues in metabolic literature. This explainer covers the molecule, the stabilisation that defines it and what published work actually describes.
What exactly is the molecule?
Tesamorelin is a synthetic 44 amino acid peptide based on human growth hormone releasing hormone, carrying a trans 3 hexenoyl group attached to the first residue.
That single modification is the point of the molecule. Native GHRH is cleaved rapidly by dipeptidyl peptidase 4, and the stabilised analogue was designed so laboratory work on GHRH receptor signalling is not limited by that speed.
Which research pathways involve it?
- GHRH receptor binding and activation in cellular models.
- Pulsatile growth hormone release and the downstream GH and IGF-1 axis.
- Visceral adipose tissue and lipid metabolism models.
- Comparative work against other GHRH analogues and against ghrelin receptor secretagogues.
Which formats are supplied?
- Tesamorelin 5mg lyophilised vial, for smaller prepared batches.
- Tesamorelin 10mg lyophilised vial, for larger study batches.
- Both are reconstituted in the laboratory, so the prepared concentration stays under researcher control.
How is it handled in the laboratory?
Store the unopened vial at -20°C, protected from light. After reconstitution, published handling practice for lyophilised peptides applies: refrigerate, avoid repeated freeze and thaw cycles, and record the solvent, volume and date on the study log.
Recalculate concentration from the actual vial mass with the reconstitution calculator rather than reusing the arithmetic from a different vial size.
What the evidence does not establish
Published work characterises receptor activity and metabolic measures. It does not support any claim about outcomes outside those study settings, and nothing on this page is a recommendation for use in humans.
Research use only
Tesamorelin supplied by Vitality Peps is for in vitro laboratory research only. Not a medicine, not a supplement, not for human or veterinary consumption. Nothing above is dosing guidance.
Frequently asked questions
What is Tesamorelin in simple terms?
A laboratory made version of growth hormone releasing hormone, the signalling peptide that acts on the GHRH receptor. A chemical modification at the N terminus makes it more stable than the native sequence.
How does it differ from native GHRH?
Native GHRH is degraded quickly in plasma. Tesamorelin carries a trans 3 hexenoyl group on the first residue, which the literature describes as reducing that degradation and extending the window over which the molecule can be measured.
Which research pathways involve Tesamorelin?
GHRH receptor activation, pulsatile growth hormone release, the GH and IGF-1 axis, and models of visceral adipose tissue and lipid metabolism.
How does Tesamorelin compare with CJC-1295?
Both are GHRH analogues acting at the same receptor, but they differ in sequence, stabilisation strategy and described half life. The Tesamorelin and CJC-1295 comparison sets them side by side.
For research purposes only. Not for human consumption. This article is educational and references published laboratory research; it is not medical advice and does not describe an approved use of any compound.